一线口服抗病毒治疗对慢性乙型肝炎患者的血清HBcrAg抑制作

StephenW

First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients
Mak LY, Wong DKH, Cheung KS, et al
BMC Gastroenterology|March 24, 2021
NEXT
Journal Summary

This study was undertaken to investigate the profiles of serum hepatitis B core-related antigen (HBcrAg) in chronic hepatitis B (CHB) patients treated with first-line nucleos(t)ide analogues (NA): entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF). Researchers assessed serum HBcrAg in 120 treatment-naïve CHB patients receiving one of the 3 NAs (ETV: TDF: TAF = 60: 26: 34) using the Lumipulse G HBcrAg assay in a Lumipulse G1200 analyzer (Fujirebio Inc, Toyko, Japan). They evaluated serum HBcrAg levels at week 0, week 48, and week 96 of NA therapy. Although HBcrAg reduction was numerically greater in the tenofovir-treated group, the magnitude of reduction of HBcrAg levels after a 2-year first-line treatment did not differ statistically among the current first-line NAs. Future long-term trials are needed to ascertain if tenofovir exerts a more pronounced effect on HBcrAg.

Read the full article on BMC Gastroenterology.

StephenW

一线口服抗病毒治疗对慢性乙型肝炎患者的血清HBcrAg抑制作用相似
麦来，黄DKH，张克强等
BMC胃肠病学| 2021年3月24日
下一个
期刊摘要

这项研究旨在调查接受一线核苷酸（t）核苷酸类似物（NA）治疗的慢性乙型肝炎（CHB）患者的血清乙型肝炎核心相关抗原（HBcrAg）的特征：恩替卡韦（ETV），替诺福韦二吡呋酯富马酸酯（TDF）或Tenofovir alafenamide（TAF）。研究人员在Lumipulse G1200分析仪（Fujirebio Inc，Toyko，日本）中使用Lumipulse G HBcrAg测定法，评估了120名未接受过3种NAs治疗的初治CHB患者的血清HBcrAg（ETV：TDF：TAF = 60：26：34）。他们评估了NA治疗第0周，第48周和第96周的血清HBcrAg水平。尽管在替诺福韦治疗组中HBcrAg的降低在数值上更大，但在当前一线NA中，经过2年一线治疗的HBcrAg水平降低幅度没有统计学差异。需要进一步的长期试验以确定替诺福韦是否对HBcrAg发挥更明显的作用。

阅读有关BMC胃肠病学的完整文章。